• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

pyCancerSig:从全基因组测序中综合单个核苷酸、结构和微卫星突变特征进行分解,对人类癌症进行亚分类。

pyCancerSig: subclassifying human cancer with comprehensive single nucleotide, structural and microsatellite mutational signature deconstruction from whole genome sequencing.

机构信息

Department of Molecular Medicine and Surgery, Karolinska Institutet, SE-171 76, Stockholm, Sweden.

Department of Clinical Genetics, Karolinska University Hospital, SE-171 76, Stockholm, Sweden.

出版信息

BMC Bioinformatics. 2020 Apr 3;21(1):128. doi: 10.1186/s12859-020-3451-8.

DOI:10.1186/s12859-020-3451-8
PMID:32245405
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7118897/
Abstract

BACKGROUND

DNA damage accumulates over the course of cancer development. The often-substantial amount of somatic mutations in cancer poses a challenge to traditional methods to characterize tumors based on driver mutations. However, advances in machine learning technology can take advantage of this substantial amount of data.

RESULTS

We developed a command line interface python package, pyCancerSig, to perform sample profiling by integrating single nucleotide variation (SNV), structural variation (SV) and microsatellite instability (MSI) profiles into a unified profile. It also provides a command to decipher underlying cancer processes, employing an unsupervised learning technique, Non-negative Matrix Factorization, and a command to visualize the results. The package accepts common standard file formats (vcf, bam). The program was evaluated using a cohort of breast- and colorectal cancer from The Cancer Genome Atlas project (TCGA). The result showed that by integrating multiple mutations modes, the tool can correctly identify cases with known clear mutational signatures and can strengthen signatures in cases with unclear signal from an SNV-only profile. The software package is available at https://github.com/jessada/pyCancerSig.

CONCLUSIONS

pyCancerSig has demonstrated its capability in identifying known and unknown cancer processes, and at the same time, illuminates the association within and between the mutation modes.

摘要

背景

在癌症发展过程中,DNA 损伤会不断累积。癌症中经常存在大量的体细胞突变,这给基于驱动突变来描述肿瘤的传统方法带来了挑战。然而,机器学习技术的进步可以利用这些大量的数据。

结果

我们开发了一个命令行接口的 Python 包 pyCancerSig,通过将单核苷酸变异 (SNV)、结构变异 (SV) 和微卫星不稳定性 (MSI) 谱图整合到一个统一的谱图中,来进行样本分析。它还提供了一个命令,通过使用无监督学习技术——非负矩阵分解来解码潜在的癌症过程,并提供了一个命令来可视化结果。该软件包接受常见的标准文件格式(vcf、bam)。我们使用来自癌症基因组图谱计划 (TCGA) 的乳腺癌和结直肠癌队列对该程序进行了评估。结果表明,通过整合多种突变模式,该工具可以正确识别已知明确突变特征的病例,并可以增强只有 SNV 谱图时信号不明确的病例的特征。该软件包可在 https://github.com/jessada/pyCancerSig 上获得。

结论

pyCancerSig 已经证明了其在识别已知和未知癌症过程方面的能力,同时也揭示了突变模式之间和内部的关联。

相似文献

1
pyCancerSig: subclassifying human cancer with comprehensive single nucleotide, structural and microsatellite mutational signature deconstruction from whole genome sequencing.pyCancerSig:从全基因组测序中综合单个核苷酸、结构和微卫星突变特征进行分解,对人类癌症进行亚分类。
BMC Bioinformatics. 2020 Apr 3;21(1):128. doi: 10.1186/s12859-020-3451-8.
2
FIREVAT: finding reliable variants without artifacts in human cancer samples using etiologically relevant mutational signatures.FIREVAT:使用与病因相关的突变特征在人类癌症样本中无伪影地发现可靠变异。
Genome Med. 2019 Dec 17;11(1):81. doi: 10.1186/s13073-019-0695-x.
3
Classification of breast cancer patients using somatic mutation profiles and machine learning approaches.利用体细胞突变谱和机器学习方法对乳腺癌患者进行分类。
BMC Syst Biol. 2016 Aug 26;10 Suppl 3(Suppl 3):62. doi: 10.1186/s12918-016-0306-z.
4
Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.对 7815 个癌症外显子组的分析揭示了突变过程与体细胞驱动突变之间的关联。
PLoS Genet. 2018 Nov 9;14(11):e1007779. doi: 10.1371/journal.pgen.1007779. eCollection 2018 Nov.
5
Determining mutational burden and signature using RNA-seq from tumor-only samples.使用仅肿瘤样本的 RNA-seq 来确定突变负担和特征。
BMC Med Genomics. 2021 Mar 1;14(1):65. doi: 10.1186/s12920-021-00898-y.
6
MutSignatures: an R package for extraction and analysis of cancer mutational signatures.MutSignatures:一个用于提取和分析癌症突变特征的 R 包。
Sci Rep. 2020 Oct 26;10(1):18217. doi: 10.1038/s41598-020-75062-0.
7
SigsPack, a package for cancer mutational signatures.SigsPack,用于癌症突变特征的软件包。
BMC Bioinformatics. 2019 Sep 2;20(1):450. doi: 10.1186/s12859-019-3043-7.
8
Hidden Markov models lead to higher resolution maps of mutation signature activity in cancer.隐马尔可夫模型可提高癌症突变特征活动图谱的分辨率。
Genome Med. 2019 Jul 26;11(1):49. doi: 10.1186/s13073-019-0659-1.
9
Mutational Signatures in Cancer (MuSiCa): a web application to implement mutational signatures analysis in cancer samples.癌症突变特征(MuSiCa):一个用于在癌症样本中实施突变特征分析的网络应用程序。
BMC Bioinformatics. 2018 Jun 14;19(1):224. doi: 10.1186/s12859-018-2234-y.
10
Modeling clinical and molecular covariates of mutational process activity in cancer.对癌症中突变过程活性的临床和分子协变量进行建模。
Bioinformatics. 2019 Jul 15;35(14):i492-i500. doi: 10.1093/bioinformatics/btz340.

引用本文的文献

1
A review on trends in development and translation of omics signatures in cancer.癌症中组学特征的发展与转化趋势综述。
Comput Struct Biotechnol J. 2024 Feb 3;23:954-971. doi: 10.1016/j.csbj.2024.01.024. eCollection 2024 Dec.
2
Application of non-negative matrix factorization in oncology: one approach for establishing precision medicine.非负矩阵分解在肿瘤学中的应用:建立精准医学的一种方法。
Brief Bioinform. 2022 Jul 18;23(4). doi: 10.1093/bib/bbac246.
3
Signatures of copy number alterations in human cancer.人类癌症中拷贝数改变的特征。

本文引用的文献

1
Computational tools to detect signatures of mutational processes in DNA from tumours: A review and empirical comparison of performance.用于检测肿瘤 DNA 中突变过程特征的计算工具:性能的回顾和实证比较。
PLoS One. 2019 Sep 12;14(9):e0221235. doi: 10.1371/journal.pone.0221235. eCollection 2019.
2
Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations.对 7815 个癌症外显子组的分析揭示了突变过程与体细胞驱动突变之间的关联。
PLoS Genet. 2018 Nov 9;14(11):e1007779. doi: 10.1371/journal.pgen.1007779. eCollection 2018 Nov.
3
COSMIC: the Catalogue Of Somatic Mutations In Cancer.
Nature. 2022 Jun;606(7916):984-991. doi: 10.1038/s41586-022-04738-6. Epub 2022 Jun 15.
4
Premetastatic shifts of endogenous and exogenous mutational processes support consolidative therapy in EGFR-driven lung adenocarcinoma.内源性和外源性突变过程的前转移变化支持 EGFR 驱动的肺腺癌的巩固性治疗。
Cancer Lett. 2022 Feb 1;526:346-351. doi: 10.1016/j.canlet.2021.11.011. Epub 2021 Nov 12.
5
Viola: a structural variant signature extractor with user-defined classifications.Viola:一种具有用户定义分类的结构变异特征提取器。
Bioinformatics. 2022 Jan 3;38(2):540-542. doi: 10.1093/bioinformatics/btab662.
COSMIC:癌症体细胞突变目录。
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. doi: 10.1093/nar/gky1015.
4
Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition.超越微卫星检测:肿瘤突变负荷评估可识别可能对免疫检查点抑制有反应的结直肠癌亚组。
J Gastrointest Oncol. 2018 Aug;9(4):610-617. doi: 10.21037/jgo.2018.05.06.
5
ClinVar: improving access to variant interpretations and supporting evidence.ClinVar:改善变异解读和支持证据的获取。
Nucleic Acids Res. 2018 Jan 4;46(D1):D1062-D1067. doi: 10.1093/nar/gkx1153.
6
Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.突变特征揭示了在肝脏肿瘤发生过程中,风险因素和细胞过程的动态相互作用。
Nat Commun. 2017 Nov 3;8(1):1315. doi: 10.1038/s41467-017-01358-x.
7
Comprehensive Analysis of Hypermutation in Human Cancer.人类癌症中高突变的综合分析。
Cell. 2017 Nov 16;171(5):1042-1056.e10. doi: 10.1016/j.cell.2017.09.048. Epub 2017 Oct 19.
8
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.一种突变特征揭示了乳腺癌中同源重组修复缺陷背后的改变。
Nat Genet. 2017 Oct;49(10):1476-1486. doi: 10.1038/ng.3934. Epub 2017 Aug 21.
9
, an efficient and comprehensive structural variant caller for massive parallel sequencing data.,一种用于大规模平行测序数据的高效且全面的结构变异检测工具。
F1000Res. 2017 May 10;6:664. doi: 10.12688/f1000research.11168.2. eCollection 2017.
10
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.错配修复缺陷可预测实体瘤对程序性死亡受体1(PD-1)阻断疗法的反应。
Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.